Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Ties Up with Domain Therapeutics of France for GPCR-Based Drug Discovery
October 25, 2012
- ZOLL Medical Acquired by Asahi Kasei Last Year Establishes Japanese Subsidiary
October 25, 2012
- Fujifilm, Kyowa Kirin to Develop Avastin Biosimilar
October 25, 2012
- “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
- Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
- More Products, Fewer Facilities Per MR: Novartis Introduces New Marketing System
October 24, 2012
- Kaken Pharmaceutical Files NDA for Efinaconazole, 1st Topical Drug for Onychomycosis in Japan
October 24, 2012
- Former Nycomed CSO to Head General Medicine Drug Discovery Unit of Takeda
October 24, 2012
- COPD Treatment Market to Expand 2.8 Times by 2020 Compared to 2011: Fuji-Keizai
October 24, 2012
- Antiepileptic Drug Fycompa Approved in the US: Eisai
October 24, 2012
- Astellas Launches Mirabegron in US
October 24, 2012
- Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
- Astellas Receives Recommendation for Approval of Mirabegron in Europe
October 23, 2012
- Neuropathic Pain Treatment Offered Funding from JST’s Support Program: Nippon Chemiphar
October 23, 2012
- Astellas Launches Gonax for Full-Fledged Entry into Cancer Field
October 23, 2012
- Takeda Moves Up to 5th, Pfizer 1st in Patent Assets Ranking
October 22, 2012
- Chugai Succeeds in Establishing World's First Stable Cancer Stem Cell Lines
October 22, 2012
- MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
- Kyowa Kirin Suspends PIIa Study of RTA 402 in Response to Licensor’s Termination of Study
October 22, 2012
- Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey
October 19, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…